Generic MembraneBlue Availability
MEMBRANEBLUE (trypan blue - solution;ophthalmic)
Approval date: February 20, 2009
Strength(s): 0.15% [RLD]
Has a generic version of MembraneBlue been approved?
No. There is currently no therapeutically equivalent version of MembraneBlue available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of MembraneBlue. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Opthalmic methods and uses
Issued: April 16, 2002
Inventor(s): Minos Theodore; Coroneo
Ophthalmic membranes and uses are described. Intraocular membranes and structures within the eye are identified by instilling into the eye a trypan blue solution which marks in a visually identifiable manner intraocular membranes and structures within the eye.
Patent expiration dates:
- November 12, 2019✓
- November 12, 2019
Use of vital dye for facilitating surgical procedures for vitreo-retinal surgery
Issued: February 24, 2004
Inventor(s): Gerrit Reinold Jacob; Melles
A method for performing retinal membrane removal is disclosed using vital dyes which are applied to the membrane. Compositions including vital dyes which are useful in the retinal membrane removal methods are also disclosed.
Patent expiration dates:
- May 7, 2019✓
- May 7, 2019
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about MembraneBlue (trypan blue ophthalmic)
- MembraneBlue Side Effects
- During Pregnancy
- Dosage Information
- Pricing & Coupons
- Drug class: ophthalmic diagnostic agents
Other brands: VisionBlue
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|